Cash Flow from Operating Activities: A company's cash flows from operations.
BridgeBio Oncology Therapeutics, Inc (BBOT) had Cash Flow from Operating Activities of $-108.64M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-34.18M |
|
-- |
|
-- |
|
$37.49M |
|
$-37.49M |
|
$3.31M |
|
$-34.18M |
|
$-34.18M |
|
$-34.18M |
|
$-34.18M |
|
$-34.18M |
|
$-34.18M |
|
$-37.49M |
|
$-37.30M |
|
80.19M |
|
80.19M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$208.33M |
|
$0.81M |
|
$137.90M |
|
$346.22M |
|
$51.03M |
|
-- |
|
$1.81M |
|
$52.84M |
|
$293.39M |
|
$293.39M |
|
$293.39M |
|
80.23M |
|
| Cash Flow Statement Financials | |
|
Cash Flow from Operating Activities |
$-108.64M |
$-189.34M |
|
$0.77M |
|
$373.82M |
|
$76.61M |
|
$-297.21M |
|
$15.84M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-108.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.65% |
|
-11.65% |
|
-9.87% |
|
-11.65% |
|
$3.66 |
|
$-1.36 |
|
$-1.35 |
|